A. Roth
About
A. Roth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, A. Roth has authored 55 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in A. Roth's work include Colorectal Cancer Treatments and Studies (26 papers), Gastric Cancer Management and Outcomes (17 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). A. Roth is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Gastric Cancer Management and Outcomes (17 papers) and Hepatocellular Carcinoma Treatment and Prognosis (12 papers). A. Roth collaborates with scholars based in Switzerland, United States and France. A. Roth's co-authors include Laura Rubbia‐Brandt, Gilles Mentha, Stanislas Chaussade, P. Sartoretti, B. Dousset, Benoît Terris, Vincent Audard, Catherine Brézault, Olivier Soubrane and Fred T. Bosman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.
In The Last Decade
A. Roth
55 papers receiving 3.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| A. Roth Switzerland | 28 | 2.8k | 1.5k | 1.3k | 1.0k | 766 | 55 | 4.0k | ||
| Sylvain Manfrédi France | 28 | 2.3k 0.8× | 754 0.5× | 1.2k 0.9× | 1.3k 1.2× | 543 0.7× | 117 | 3.5k | ||
| Michelle R. Mahoney United States | 32 | 3.4k 1.2× | 934 0.6× | 1.7k 1.3× | 1.2k 1.1× | 1.3k 1.7× | 71 | 4.8k | ||
| J. Załuski Poland | 13 | 3.7k 1.3× | 855 0.6× | 1.7k 1.3× | 816 0.8× | 929 1.2× | 23 | 4.5k | ||
| Gérard Lledo France | 27 | 5.8k 2.1× | 1.6k 1.1× | 2.3k 1.7× | 1.7k 1.6× | 712 0.9× | 101 | 6.5k | ||
| Ilhan Celik Germany | 15 | 2.8k 1.0× | 580 0.4× | 1.6k 1.2× | 682 0.7× | 911 1.2× | 31 | 3.9k | ||
| P Rougier France | 16 | 3.1k 1.1× | 1.2k 0.8× | 1.2k 0.9× | 959 0.9× | 486 0.6× | 70 | 3.9k | ||
| Dominik Paul Modest Germany | 36 | 3.5k 1.3× | 900 0.6× | 1.6k 1.2× | 833 0.8× | 1.1k 1.5× | 206 | 4.4k | ||
| Arnaud Roth Switzerland | 34 | 3.4k 1.2× | 661 0.5× | 1.8k 1.4× | 1.3k 1.2× | 1.4k 1.9× | 115 | 5.1k | ||
| Côme Lepage France | 39 | 3.5k 1.3× | 988 0.7× | 1.5k 1.1× | 1.8k 1.7× | 993 1.3× | 214 | 5.3k | ||
| Claus‐Henning Köhne Germany | 27 | 3.1k 1.1× | 1.1k 0.8× | 1.2k 0.9× | 750 0.7× | 627 0.8× | 75 | 4.3k |
Countries citing papers authored by A. Roth
Since
Specialization
Citations
This map shows the geographic impact of A. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Roth more than expected).
Fields of papers citing papers by A. Roth
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by A. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Roth. The network helps show where A. Roth may publish in the future.
Co-authorship network of co-authors of A. Roth
This figure shows the co-authorship network connecting the top 25 collaborators of A. Roth. A scholar is included among the top collaborators of A. Roth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Roth. A. Roth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Koeberle, Dieter, Jean‐François Dufour, Gyula Demeter, et al.. (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology. 27(5). 856–861.
2.
Folprecht, Gunnar, Philip Beer, Ramón Salazar, et al.. (2016). Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor. Annals of Oncology. 27. vi151–vi151.
3.
Koeberle, Dieter, Daniel Betticher, Roger von Moos, et al.. (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology. 26(4). 709–714.
4.
Heim, Christine, A. Roth, Jocelyne Bloch, et al.. (2014). Is trauma in Switzerland any different? Epidemiology and patterns of injury in major trauma – a 5-year review from a Swiss trauma centre. Swiss Medical Weekly. 144(1314). w13958–w13958.
5.
Missiaglia, Edoardo, Bart Jacobs, Antonio Fabio Di Narzo, et al.. (2014). Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of Oncology. 25(10). 1995–2001.
6.
Klingbiel, Dirk, Zacharenia Saridaki, A. Roth, et al.. (2014). Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Annals of Oncology. 26(1). 126–132.
7.
Roth, A., Mauro Delorenzi, Sabine Tejpar, et al.. (2012). Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. JNCI Journal of the National Cancer Institute. 104(21). 1635–1646.
8.
Roth, A., Dirk Klingbiel, Ping Yan, et al.. (2010). Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial. Annals of Oncology. 21. 16–16.
9.
Roth, A., Dirk Klingbiel, Roberto Fiocca, et al.. (2010). Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.. Journal of Clinical Oncology. 28(15_suppl). 3504–3504.
10.
Roth, A., Sabine Tejpar, Ping Yan, et al.. (2009). Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial. Annals of Oncology. 20. 7–7.
11.
Montemurro, Michael, Patrick Schöffski, Peter Reichardt, et al.. (2009). Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. European Journal of Cancer. 45(13). 2293–2297.
12.
Mentha, Gilles, Sylvain Terraz, Philippe Morel, et al.. (2008). Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. British journal of surgery. 96(1). 95–103.
13.
Mentha, Gilles, Pietro Majno, Sylvain Terraz, et al.. (2007). Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. European Journal of Surgical Oncology. 33. S76–S83.
14.
Rubbia‐Brandt, Laura, Emiliano Giostra, Catherine Brézault, et al.. (2006). Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of Oncology. 18(2). 299–304.
15.
Stahel, Rolf A., Daniel Betticher, Ralph A. Schmid, et al.. (2004). Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (MPM): A multicenter phase II trial of the SAKK. Journal of Clinical Oncology. 22(14_suppl). 7052–7052.
16.
Roth, A. & Jaffer A. Ajani. (2003). Docetaxel-based chemotherapy in the treatment of gastric cancer. Annals of Oncology. 14. ii41–ii44.
17.
Roth, A., Abdelkarim S. Allal, Marie‐Anne Bründler, et al.. (2002). Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I–II study. Annals of Oncology. 14(1). 110–115.
18.
Cutsem, Eric Van, M. Dicato, J. Wils, et al.. (2002). Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). European Journal of Cancer. 38(11). 1429–1436.
19.
Betticher, Daniel, S.‐F. Hsu Schmitz, A. Roth, et al.. (2000). Neoadjuvant therapy with Docetaxel (TAX) and Cisplatin (CIS) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA, N2 is highly active with few toxicities. Lung Cancer. 29(1). 99–99.
20.
Hauser, Carl J., et al.. (1990). A patient with features of both Bardet-Biedl and Alström syndromes. European Journal of Pediatrics. 149(11). 783–785.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sylvain Manfrédi Breakdown of academic impact, for papers by Michelle R. Mahoney Breakdown of academic impact, for papers by J. Załuski Breakdown of academic impact, for papers by Gérard Lledo Breakdown of academic impact, for papers by Ilhan Celik Breakdown of academic impact, for papers by P Rougier Breakdown of academic impact, for papers by Dominik Paul Modest Breakdown of academic impact, for papers by Arnaud Roth Breakdown of academic impact, for papers by Côme Lepage Breakdown of academic impact, for papers by Claus‐Henning Köhne